MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (indian pharma)
- GLENMARK PHARMA
GLENMARK PHARMA Share Price (GLPH)
Here is the latest stock price and chart of Glenmark Pharma. For more details, see the Glenmark Pharma company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Nov 18, 2019 12:33:00 PM | ||
|---|---|---|---|
| Price (Rs)346.85 | Open (Rs) 308.00 | High (Rs) 350.35 | Low (Rs) 308.00 |
| % Change15.16 | Volume 696,184 | Value (Rs) 241,471,420 | 52-Week H/L 706.90 / 267.30 |
| Live NSE Quotes | Nov 18, 2019 12:34:59 PM | ||
|---|---|---|---|
| Price (Rs)347.35 | Open (Rs) 310.40 | High (Rs) 350.70 | Low (Rs) 310.40 |
| % Change15.40 | Volume 16,693,725 | Value (Rs) 5,610,594,035 | 52-Week H/L 705.90 / 267.25 |
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 28.40 | P/E Ratio (x) 12.21 | Market Cap (Rs m) 97,869.97 | P/BV (x) 1.75 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
Listen In: Our Investor Hour Podcast Connects You with the World's Most Successful Investors
- Charts
-
S&P BSE SENSEX 
PERIOD - Advanced Charts new
- Charts by TradingView
GLENMARK PHARMA Share Price Today:
GLENMARK PHARMA share price has zoomed 15.2% to Rs 346.9 on the BSE. On the NSE, the GLENMARK PHARMA share price has zoomed 15.4% to Rs 347.4. The total volume of shares traded is 17.4 m.
Overall, the broader S&P BSE HEALTHCARE Index is trading up by 1.1%. And the benchmark S&P BSE SENSEX is at 40,238.4 (down 0.3%).
Over the last 30 days, the GLENMARK PHARMA share price is up 21.1%. And over the last one year, GLENMARK PHARMA share price is down 47.8%.
|
| |
Today's Market
Sensex Turns Negative; Yes Bank and Bajaj Auto Top Losers(12:30 pm)
Stock markets in India are presently trading on a negative note. The BSE Sensex is trading down by 116 points and the NSE Nifty is trading down by 22 points.
Related Views On News
PARAG MILK FOODS LTD Surges by 10%; BSE 500 Index Down 0.1% (Market Updates)
Nov 18, 2019 | Updated on Nov 18, 2019PARAG MILK FOODS LTD share price has surged by 10% and its current market price is Rs 140. The BSE 500 is down by 0.1%. The top gainers in the BSE 500 Index are PARAG MILK FOODS LTD (up 10.3%) and GLENMARK PHARMA (up 14.9%). The top losers are J.B.CHEMICALS and G.E.SHIPPING .
WOCKHARDT Surges by 11%; BSE HEALTHCARE Index Up 1.0% (Market Updates)
Nov 18, 2019 | Updated on Nov 18, 2019WOCKHARDT share price has surged by 11% and its current market price is Rs 306. The BSE HEALTHCARE is up by 1.0%. The top gainers in the BSE HEALTHCARE Index are WOCKHARDT (up 11.3%) and GLENMARK PHARMA (up 14.7%). The top losers are LAURUS LABS LTD and BLISS GVS PHARMA .
WOCKHARDT Surges by 8%; BSE HEALTHCARE Index Up 0.7% (Market Updates)
Nov 18, 2019 | Updated on Nov 18, 2019WOCKHARDT share price has surged by 8% and its current market price is Rs 302. The BSE HEALTHCARE is up by 0.7%. The top gainers in the BSE HEALTHCARE Index are WOCKHARDT (up 7.9%) and GLENMARK PHARMA (up 7.9%). The top losers are BLISS GVS PHARMA and CAPLIN POINT .
GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Sep 5, 2019 | Updated on Sep 5, 2019Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.
GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)
Aug 28, 2019 | Updated on Aug 28, 2019For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
More Views on NewsMost Popular
Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints? (Profit Hunter)
Nov 7, 2019Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?
Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks (The 5 Minute Wrapup)
Nov 8, 2019Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.
These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound (Profit Hunter)
Nov 5, 2019How to avoid the most common investing mistake and make the most of the smallcap rebound.
The Top Stocks for 2020 Pass This Most Critical Metric (The 5 Minute Wrapup)
Nov 5, 2019Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.
A Trade that Could Generate Profits for Decades
Nov 14, 2019India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...
MoreTRACK GLENMARK PHARMA
- Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON GLENMARK PHARMA
GLENMARK PHARMA - MYLAN COMPARISON
COMPARE GLENMARK PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.